Polyrizon's Naloxone Formulation Shows Superior Nasal Deposition in Comparative Study
Event summary
- Polyrizon's naloxone formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate, compared to 79.6% for the commercial reference product.
- The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the supervision of Prof. Fabio Sonvico.
- Polyrizon’s formulation showed significantly lower deposition in the lower turbinate region (5.4% vs. 20.4% for the commercial product).
- The results validate Polyrizon’s Trap & Target™ technology for controlled regional deposition within the nasal cavity.
The big picture
Polyrizon’s successful study highlights the potential of its Trap & Target™ technology to improve drug delivery efficiency, a critical factor in the competitive intranasal drug market. The results suggest a strategic advantage in targeting highly vascularized nasal regions, which could enhance systemic absorption and bioavailability. This positions Polyrizon as a key player in the development of next-generation intranasal therapies.
What we're watching
- Technology Validation
- Whether Polyrizon can translate these pre-clinical results into clinical success and regulatory approval.
- Market Differentiation
- How the enhanced deposition profile will position Polyrizon’s naloxone formulation against existing commercial products.
- Platform Expansion
- The pace at which Polyrizon advances its broader intranasal platform strategy beyond naloxone.
Related topics